Akoya Biosciences Stock Performance
| AKYA Stock | USD 1.74 0.02 1.14% |
The firm shows a Beta (market volatility) of -0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Akoya Biosciences are expected to decrease at a much lower rate. During the bear market, Akoya Biosciences is likely to outperform the market. At this point, Akoya Biosciences has a negative expected return of -0.26%. Please make sure to confirm Akoya Biosciences' maximum drawdown, as well as the relationship between the daily balance of power and price action indicator , to decide if Akoya Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Akoya Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Akoya Biosciences SWOT analysis spatial proteomics firm faces headwinds | 12/04/2024 |
2 | Disposition of 25000 shares by Pascal Bamford of Akoya Biosciences at 12.3 subject to Rule 16b-3 | 12/06/2024 |
3 | Nature Methods Names Spatial Proteomics Method of the Year 2024 -- Akoya ... | 12/09/2024 |
4 | Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stag... | 12/10/2024 |
5 | Akoya Biosciences, Inc. Receives Average Recommendation of Hold from Brokerages - MarketBeat | 12/30/2024 |
6 | AKYA Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders | 01/10/2025 |
7 | Akoya Biosciences Cut to Hold at Canaccord Genuity Group | 01/15/2025 |
8 | Disposition of 226 shares by Brian McKelligon of Akoya Biosciences at 9.918 subject to Rule 16b-3 | 01/27/2025 |
9 | Akoya Biosciences unveils strategic product roadmap - Yahoo Finance | 02/06/2025 |
10 | Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Companys Proposed Merger with Akoya Biosciences | 02/18/2025 |
| Begin Period Cash Flow | 74.5 M |
Akoya |
Akoya Biosciences Relative Risk vs. Return Landscape
If you would invest 220.00 in Akoya Biosciences on November 29, 2024 and sell it today you would lose (44.00) from holding Akoya Biosciences or give up 20.0% of portfolio value over 90 days. Akoya Biosciences is currently does not generate positive expected returns and assumes 4.8753% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Akoya, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Akoya Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akoya Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akoya Biosciences, and traders can use it to determine the average amount a Akoya Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0535
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AKYA |
Estimated Market Risk
| 4.88 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Akoya Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akoya Biosciences by adding Akoya Biosciences to a well-diversified portfolio.
Akoya Biosciences Fundamentals Growth
Akoya Stock prices reflect investors' perceptions of the future prospects and financial health of Akoya Biosciences, and Akoya Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akoya Stock performance.
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.67) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 136.27 M | ||||
| Shares Outstanding | 49.57 M | ||||
| Price To Book | 6.40 X | ||||
| Price To Sales | 1.00 X | ||||
| Revenue | 96.63 M | ||||
| Gross Profit | 50.11 M | ||||
| EBITDA | (45.63 M) | ||||
| Net Income | (63.32 M) | ||||
| Cash And Equivalents | 87.61 M | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 85.71 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.55 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (50.9 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 87.25 M | ||||
| Total Asset | 180.37 M | ||||
| Retained Earnings | (230.07 M) | ||||
| Working Capital | 86.44 M | ||||
About Akoya Biosciences Performance
By analyzing Akoya Biosciences' fundamental ratios, stakeholders can gain valuable insights into Akoya Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Akoya Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Akoya Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 145.62 | 106.86 | |
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (1.35) | (1.42) |
Things to note about Akoya Biosciences performance evaluation
Checking the ongoing alerts about Akoya Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akoya Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akoya Biosciences generated a negative expected return over the last 90 days | |
| Akoya Biosciences may become a speculative penny stock | |
| Akoya Biosciences has high historical volatility and very poor performance | |
| Akoya Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 96.63 M. Net Loss for the year was (63.32 M) with profit before overhead, payroll, taxes, and interest of 50.11 M. | |
| Akoya Biosciences currently holds about 87.61 M in cash with (50.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Companys Proposed Merger with Akoya Biosciences |
- Analyzing Akoya Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akoya Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Akoya Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akoya Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akoya Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akoya Biosciences' stock. These opinions can provide insight into Akoya Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Akoya Stock analysis
When running Akoya Biosciences' price analysis, check to measure Akoya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akoya Biosciences is operating at the current time. Most of Akoya Biosciences' value examination focuses on studying past and present price action to predict the probability of Akoya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akoya Biosciences' price. Additionally, you may evaluate how the addition of Akoya Biosciences to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |